Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by duskwon Nov 22, 2012 8:24pm
446 Views
Post# 20634019

RE: No Comments from KerBer?

RE: No Comments from KerBer?

Interesting points. It's hard to see what the market will determine a fair earnings multiple is for HEM. I think a high multiple in the 12x range won't be possible until HEM can show CONSISTENT earnings. That won't be apparently throughout 2013. Any potential EPS growth will have to be demonstrated before the value of the shares is apparently. I'm afraid that won't be until latter 2013 or even into 2014. I think we'll be range bound between 60c and 80c for the next 6-8 months at least; at least without any catalyst news.

 

That said, I'm aligned with Ben G. I'd rather take 1.25 to 1.50 right now versus waiting. It's about risk vs. reward. I think there is very little risk at these levels, but Ithe near-term upside is limited. Anyway considering the CEO RH and the guy from AgJ hold a significant percentage, I suspect the new strategy will prevail.

 

That said, I think if a venture fund were to make a run at this one, and get a few other institutions on board, they could privatize this beast around $1.25 today, split 'er up, and make some money along the way... just sayin ...

 

Bullboard Posts